FDA OKs Tofacitinib (Xeljanz) for Active Psoriatic Arthritis FDA OKs Tofacitinib (Xeljanz) for Active Psoriatic Arthritis

The JAK inhibitor is indicated for patients who have failed to respond adequately or are intolerant to methotrexate or other disease-modifying antirheumatic drugs.FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news